Iritec (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cancer cells to SN‑38, an active metabolite that inhibits topoisomerase I. This enzyme normally relaxes DNA during replication; its inhibition creates DNA strand breaks that cannot be repaired, leading to tumor cell death.

The specific dose of Iritec is determined by the prescribing oncologist based on the patient’s weight, disease stage, and treatment protocol. Typical regimens involve an intravenous infusion given every two weeks, but exact dosing and schedule are individualized and must follow the prescriber’s orders.

Safety of Iritec during pregnancy and lactation has not been established. It is generally contraindicated because of potential harm to the fetus or nursing infant. Women of child‑bearing potential should use effective contraception and discuss risks with their healthcare provider.

To order Iritec, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Iritec belongs to the topoisomerase I inhibitor class, similar to topotecan. Compared with topotecan, irinotecan has a longer half‑life and is often used in colorectal cancer regimens, whereas topotecan is more common in ovarian and small‑cell lung cancer. Choice depends on tumor type, prior therapy and physician judgment.

Iritec must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before administration, allow the solution to reach room temperature if required and inspect for particulate matter.

Iritec is administered by intravenous infusion. The prepared solution is infused over a prescribed period, usually 30 to 90 minutes, under the supervision of qualified medical staff. Infusion rates and pre‑medication (e.g., anti‑emetics) are determined by the treating oncologist.

The most serious adverse events include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, and hypersensitivity reactions that can progress to anaphylaxis. Prompt medical attention is required if patients develop high fever, persistent diarrhea, or signs of an allergic reaction.

Iritec should be avoided in patients with known hypersensitivity to irinotecan or any formulation component, those with severe bone‑marrow suppression, uncontrolled infections, or recent bowel obstruction. Caution is also advised for individuals with significant hepatic impairment or who are pregnant.